Therachon
Signal active
Organization
Contact Information
Overview
Therachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead pipeline candidate, TA-46, is a novel protein therapy in development for achondroplasia, the most common form of short-limbed dwarfism. Therachon is headquartered in Basel, Switzerland, with research labs in Nice, France.
About
Industries
Biotechnology, Medical, Therapeutics
Founded
2014
Employees
1-10
Headquarters locations
Switzerland, Europe
Social
N/A
Profile Resume
Therachon headquartered in Switzerland, Europe, operates in the Biotechnology, Medical, Therapeutics sector. The company focuses on Biotechnology and has secured $3.6B in funding across 36 round(s). With a team of 1-10 employees, Therachon is actively contributing to advancements in Biotechnology. Their latest funding round, Series A - Therachon, raised $35.0M. Discover more about their projects, partnerships, and impact on our platform.
Employees
N/A
Funding Rounds
Funding rounds
3
Investors
4
Lead Investors
0
Total Funding Amount
$100.0M
Details
3
Therachon has raised a total of $100.0M in funding over 3 rounds.
| Announcement date | Transaction name | Number of Investors | Money raised | Lead Investor |
|---|---|---|---|---|
| 2018 | Early Stage Venture | 60.0M | ||
| 2017 | Early Stage Venture | 5.0M | ||
| 2015 | Early Stage Venture | 35.0M |
Investors
Therachon is funded by 31 investors.
| Investor Name | Lead Investor | Funding Round | Partners |
|---|---|---|---|
| Inserm Transfert Initiative | - | FUNDING ROUND - Inserm Transfert Initiative | 35.0M |
| Tom Woiwode | - | FUNDING ROUND - Tom Woiwode | 35.0M |
| Therachon | - | FUNDING ROUND - Therachon | 35.0M |
| Versant Ventures | - | FUNDING ROUND - Versant Ventures | 35.0M |
Recent Activity
There is no recent news or activity for this profile.